Advertisement
A vs TMO
Which Stock Would AI Choose? Agilent Technologies (A) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- A and TMO operate in the life sciences and analytical instruments sector, with TMO offering greater scale through diversified services and A focusing on precision measurement tools.
- Recent market activity shows A trading near $115 with a 52-week range of approximately $107–$160, while TMO trades near $448 within a broader $385–$644 range.
- A reported new product launches in recent weeks, including advanced mass spectrometry systems, supporting sentiment in its core analytical chemistry markets.
- TMO completed the sale of its microbiology business for about $1.08 billion and noted ongoing softness in academic and government demand during its latest earnings cycle.
- Year-to-date returns reflect mixed relative performance, with both stocks facing sector headwinds but exhibiting different volatility profiles—A showing higher beta than TMO.
- Market positioning contrasts highlight TMO’s larger revenue base and service offerings versus A’s higher operating margins in specialized instrumentation.
Introduction
Agilent Technologies (A) and Thermo Fisher Scientific (TMO) represent two established players in the life sciences tools and diagnostics industry. This comparison examines their business models, recent stock behavior, and key differentiators to assist investors and traders evaluating exposure within the healthcare equipment and services sector. Market participants focused on relative performance, sector rotation, or portfolio diversification in analytical instruments and biopharma support services may find the analysis relevant. The review draws on observable price action, corporate developments, and positioning over recent weeks without forward-looking projections.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies provides analytical instruments, software, and services for life sciences, applied chemical markets, and diagnostics. Its portfolio centers on chromatography, mass spectrometry, and spectroscopy solutions used in research, quality control, and clinical applications. In recent market activity, shares have traded in a range influenced by broader life sciences demand and new product introductions. Recent weeks featured launches such as the Agilent 9500 Triple Quadrupole ICP-MS system and the 1290 Infinity III Fluorescence Detector, which analysts noted as potential catalysts for instrument sales momentum. The stock has shown resilience relative to some sector peers amid mixed macroeconomic signals, though it remains below its 52-week high. Sentiment has been supported by consistent dividend announcements and operational focus on high-margin segments.
Thermo Fisher Scientific (TMO) Overview and Recent Performance
Thermo Fisher Scientific offers a broad range of life sciences solutions, including laboratory equipment, reagents, consumables, and biopharma services. The company serves academic, government, pharmaceutical, and industrial customers globally. Recent performance reflects a large-scale divestiture alongside ongoing demand variability. In recent weeks, TMO completed the sale of its microbiology business to a private equity firm for approximately $1.08 billion. Earnings commentary highlighted subdued recovery expectations for U.S. and Chinese academic and government spending. Shares have experienced pressure from these factors, trading well below earlier 2026 peaks within a wide 52-week range. Market positioning emphasizes scale in services and diagnostics, with sentiment shaped by operational updates and sector-wide funding trends.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section on its platform. The site features hundreds of AI trading bots that operate across thousands of tickers, employing varied strategies, timeframes, and performance metrics. Only those demonstrating strong suitability for prevailing market conditions appear in the trending roster. Available bots display a range of historical win rates, profit factors, and drawdown statistics, allowing users to review detailed backtesting data and ticker-specific applicability. Different bots emphasize distinct approaches, such as momentum, mean-reversion, or multi-factor models. This section provides transparent access to quantitative trading tools for market participants seeking data-driven options. Review the full selection at Trending AI Robots.
Head-to-Head Comparison
Business models differ markedly: A concentrates on specialized analytical instrumentation with higher gross margins, while TMO leverages integrated services, consumables, and larger contract manufacturing capabilities for scale. Growth drivers for A center on laboratory capital spending and new instrument adoption; TMO benefits from recurring revenue streams in biopharma and diagnostics but faces greater exposure to academic funding cycles. Recent momentum shows A supported by product innovation, whereas TMO contends with divestiture-related adjustments and demand softness. Risk factors include A’s higher beta volatility versus TMO’s larger balance sheet but potential margin compression in services. Sector exposure overlaps in life sciences yet contrasts in end-market weighting—research tools for A and broader healthcare services for TMO. Market sentiment remains neutral to cautious for both amid macroeconomic variables.
Tickeron AI Verdict
Based on observable factors such as trend consistency in recent price action, stability of core end markets, and near-term catalysts, Tickeron’s AI models would currently assign a modestly higher probabilistic preference to A over TMO. This reflects A’s product-driven momentum and relatively contained exposure to academic funding variability, though both equities carry sector-specific risks that warrant ongoing monitoring.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and TMO is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 4 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s).
- A’s TA Score: 4 bullish, 6 bearish.
- TMO’s TA Score: 3 bullish, 7 bearish.
Price Growth
A (@Medical Specialties) experienced а -4.13% price change this week, while TMO (@Medical Specialties) price change was -0.73% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.27%. For the same industry, the average monthly price growth was +8.03%, and the average quarterly price growth was -5.20%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
TMO is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Medical Specialties (-0.27% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | TMO | A / TMO | |
| Capitalization | 36.7B | 174B | 21% |
| EBITDA | 1.96B | 11.7B | 17% |
| Gain YTD | -4.190 | -18.922 | 22% |
| P/E Ratio | 26.07 | 25.80 | 101% |
| Revenue | 7.23B | 45.2B | 16% |
| Total Cash | 1.81B | 3.26B | 55% |
| Total Debt | 3.36B | 43.2B | 8% |
A | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 40 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 95 | 93 | |
SMR RATING 1..100 | 44 | 62 | |
PRICE GROWTH RATING 1..100 | 46 | 54 | |
P/E GROWTH RATING 1..100 | 63 | 47 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (6) in the Biotechnology industry is in the same range as TMO (12) in the Medical Specialties industry. This means that A’s stock grew similarly to TMO’s over the last 12 months.
TMO's Profit vs Risk Rating (93) in the Medical Specialties industry is in the same range as A (95) in the Biotechnology industry. This means that TMO’s stock grew similarly to A’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is in the same range as TMO (62) in the Medical Specialties industry. This means that A’s stock grew similarly to TMO’s over the last 12 months.
A's Price Growth Rating (46) in the Biotechnology industry is in the same range as TMO (54) in the Medical Specialties industry. This means that A’s stock grew similarly to TMO’s over the last 12 months.
TMO's P/E Growth Rating (47) in the Medical Specialties industry is in the same range as A (63) in the Biotechnology industry. This means that TMO’s stock grew similarly to A’s over the last 12 months.
| A | TMO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 70% | 2 days ago 55% |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 57% |
| Momentum ODDS (%) | 2 days ago 58% | 2 days ago 57% |
| MACD ODDS (%) | 2 days ago 64% | 2 days ago 62% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 61% |
| Advances ODDS (%) | 10 days ago 60% | 13 days ago 62% |
| Declines ODDS (%) | 3 days ago 62% | 2 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 66% | 2 days ago 55% |
| Aroon ODDS (%) | 2 days ago 69% | 2 days ago 63% |
Advertisement
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.